Study on the optimisation of clinical protocols and efficacy mechanisms of Traditional Chinese Medicine in the prevention and treatment of attention deficit hyperactivity disorder in children

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400082223

Enrollment

Unknown

Registered

2024-03-25

Start date

2024-03-25

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Interventions

Treatment group:Jingning Fang

Control group:Jingning Fang Placebo

Eligibility

Sex/Gender

All

Age

6 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1: Meet the diagnostic criteria of Western medicine regarding attention deficit hyperactivity disorder 2: Comply with the Chinese medicine diagnostic criteria on qi and yin deficiency evidence of hyperactivity disorder in children; 3: Age =6 years old, 80 6: Parents (guardians) and children agreed to participate in the trial, and both or one of the parents (guardians) and children had to sign an informed consent form (children aged <8 years did not need to sign an informed consent form, but only to make informed notification)

Exclusion criteria

Exclusion criteria: 1: Persons with comorbid other psychiatric disorders, pervasive developmental disorders, mental retardation, and a history of suicide or self-injury (possible comorbidity with depressive disorders) need to be excluded 2: Persons with comorbidities to experimental medications, or other systemic serious illnesses 3: Exclude those with a current or recent (within 6 months prior to study entry) history of substance abuse or dependence 4: Exclusion is required for those who have had ineffective prior treatment with the test medication, or any other condition that, in the opinion of the investigator, interferes with the evaluation of the effectiveness and safety of the test medication

Design outcomes

Primary

Measure	Time frame
Chinese version of Swan-son Nolan and Pelham, Version IV Scale-parent form, SNAP-IV;	—

Secondary

Measure	Time frame
Weiss functional impairment rating scale, parent form;The evaluation traditional Chinese medicine syndrome;Clinical Global Impression-Severity scale;Clinical Global Impressions-Improvement;liver and renal function;ECG;	—

Countries

China

Contacts

Public ContactWang Junhong

Dongzhimen Hospital, Beijing University of Chinese Medicine

drjhwang@bucm.edu.cn+86 10 8401 3158

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026